Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Prostate cancer, version 2.2014.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 May;12(5):686-718.

PMID:
24812137
2.

Prostate cancer, version 1.2014.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2013 Dec 1;11(12):1471-9.

PMID:
24335682
3.

Current clinical presentation and treatment of localized prostate cancer in the United States.

Mahmood U, Levy LB, Nguyen PL, Lee AK, Kuban DA, Hoffman KE.

J Urol. 2014 Dec;192(6):1650-6. doi: 10.1016/j.juro.2014.06.017. Epub 2014 Jun 12.

PMID:
24931803
4.

Modification and implementation of NCCN guidelines on prostate cancer in the Middle East and North Africa region.

Hassen WA, Karsan FA, Abbas F, Beduk Y, El-Khodary A, Ghosn M, Khader J, Khauli R, Rabah DM, Shamseddine A, Srinivas S; MENA Prostate Cancer Regional Guidelines Committee.

J Natl Compr Canc Netw. 2010 Jul;8 Suppl 3:S26-8.

PMID:
20697128
5.

Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1211-9; quiz 1219.

PMID:
25190691
6.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
7.

The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.

Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME.

Arch Pathol Lab Med. 2014 Oct;138(10):1387-405. doi: 10.5858/arpa.2014-0219-SA. Epub 2014 Aug 5. Review.

PMID:
25092589
8.

Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.

Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.

J Clin Oncol. 2012 Sep 1;30(25):3071-6. doi: 10.1200/JCO.2012.42.8466. Epub 2012 Jul 30.

PMID:
22851571
9.

What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.

Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE Investigators.

J Urol. 2008 Oct;180(4):1330-4; discussion 1334-5. doi: 10.1016/j.juro.2008.06.019. Epub 2008 Aug 15.

PMID:
18707731
10.

Prostate cancer. NCCN clinical practice guidelines in oncology.

National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2004 May;2(3):224-48.

PMID:
19795607
11.

Early outcomes of active surveillance for localized prostate cancer.

Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D.

BJU Int. 2005 May;95(7):956-60.

12.

Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.

Jonsson E, Sigbjarnarson HP, Tomasson J, Benediktsdottir KR, Tryggvadottir L, Hrafnkelsson J, Olafsdottir EJ, Tulinius H, Jonasson JG.

Scand J Urol Nephrol. 2006;40(4):265-71.

PMID:
16916765
13.

EAU guidelines on prostate cancer.

Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, Zattoni F; EAU Working Group on Oncological Urology.

Eur Urol. 2001 Aug;40(2):97-101.

PMID:
11528184
14.

Screening and management of prostate cancer in elderly men: the Iowa Prostate Cancer Consensus.

Konety BR, Sharp VJ, Raut H, Williams RD.

Urology. 2008 Mar;71(3):511-4. doi: 10.1016/j.urology.2007.09.019.

PMID:
18342199
15.

[Adenocarcinoma of the prostate].

Dvorácek J.

Cas Lek Cesk. 1998 Aug 31;137(17):515-21. Review. Czech.

PMID:
9787503
16.

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA; National Comprehensive Cancer Networks.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):703-13.

17.

ACR Appropriateness Criteria prostate cancer--pretreatment detection, staging, and surveillance.

Eberhardt SC, Carter S, Casalino DD, Merrick G, Frank SJ, Gottschalk AR, Leyendecker JR, Nguyen PL, Oto A, Porter C, Remer EM, Rosenthal SA.

J Am Coll Radiol. 2013 Feb;10(2):83-92. doi: 10.1016/j.jacr.2012.10.021.

PMID:
23374687
18.

Models of care and NCCN guideline adherence in very-low-risk prostate cancer.

Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.

J Natl Compr Canc Netw. 2013 Nov;11(11):1364-72.

PMID:
24225970
19.

[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F.

Actas Urol Esp. 2011 Oct;35(9):501-14. doi: 10.1016/j.acuro.2011.04.004. Epub 2011 Jul 14. Spanish.

PMID:
21757259
20.

Prostate Cancer, Version 1.2016.

Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.

PMID:
26733552

Supplemental Content

Support Center